Skip to main content

MoneyWorks4Me

Natco Pharma informs about press release

21 Nov 2026 Evaluate
Natco Pharma has enclosed the intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 on the US Food and Drug Administration (FDA) inspection at the Formulations Manufacturing facility located in Kothur, Hyderabad, India, from 12th November to 20th November, 2026.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1885.10
Dr. Reddys Labs. 1390.50
Cipla 1414.95
Lupin 2010.00
Zydus Lifesciences 1195.05
View more..